| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2145962 | Molecular Oncology | 2012 | 12 Pages |
Abstract
⺠KRAS and secondary EGFR mutations confer resistance to EGFR inhibitors. ⺠Upregulation of parallel signaling pathways is a frequent adoptive response. ⺠Irreversible EGFR TKIs may overtake resistance in lung cancer. ⺠More efficient anti-EGFR mAbs are promising agents in colorectal cancer. ⺠Combination of targeted agents is a straightforward approach under investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, Josep Tabernero,